Rosa María Ayala

33PUBLICATIONS
190CO-AUTHORS
NanomedicineMedical infection agents (incl. prions)Haematological tumoursEpigenetics (incl. genome methylation and epigenomics)Diagnostic radiography
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Oct 06, 2026
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry.

|Aug 31, 2026
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

|Aug 04, 2026
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

|Jul 13, 2026
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

|May 07, 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group.

|Oct 31, 2025
Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.

Alberto Blanco-Sánchez, Rosa Ayala, Gonzalo Carreño-Tarragona

Pageof 6

Frequent Collaborators

15 joint publications

Joaquín Martínez-López

10 joint publications

Gonzalo Carreño-Tarragona

7 joint publications

Mar Tormo

7 joint publications

Pau Montesinos